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ABSTRACT
Patients with advanced hepatocellular carcinoma (HCC) 
have historically had few options and faced extremely 
poor prognoses if their disease progressed after standard- 
of- care tyrosine kinase inhibitors (TKIs). Recently, the 
standard of care for HCC has been transformed as a 
combination of the immune checkpoint inhibitor (ICI) 
atezolizumab plus the anti- vascular endothelial growth 
factor (VEGF) antibody bevacizumab was shown to 
offer improved overall survival in the first- line setting. 
Immunotherapy has demonstrated safety and efficacy 
in later lines of therapy as well, and ongoing trials are 
investigating novel combinations of ICIs and TKIs, in 
addition to interventions earlier in the course of disease 
or in combination with liver- directed therapies. Because 
HCC usually develops against a background of cirrhosis, 
immunotherapy for liver tumors is complex and oncologists 
need to account for both immunological and hepatological 
considerations when developing a treatment plan for their 
patients. To provide guidance to the oncology community 
on important concerns for the immunotherapeutic care 
of HCC, the Society for Immunotherapy of Cancer (SITC) 
convened a multidisciplinary panel of experts to develop a 
clinical practice guideline (CPG). The expert panel drew on 
the published literature as well as their clinical experience 
to develop recommendations for healthcare professionals 
on these important aspects of immunotherapeutic 
treatment for HCC, including diagnosis and staging, 
treatment planning, immune- related adverse events 
(irAEs), and patient quality of life (QOL) considerations. 
The evidence- and consensus- based recommendations 
in this CPG are intended to give guidance to cancer care 
providers treating patients with HCC.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the most 
common primary cancer of the liver and is 
among the top causes of cancer- related death 
worldwide.1 Mortality due to HCC exerts a 
high human toll in most countries around the 
world, and in the United States (US), the inci-
dence has increased markedly in recent years.2 
Risk factors for HCC are unevenly distributed 
around the globe. In the USA, Europe, and 
Japan, the predominant risk factors for HCC 
are overweight- related and obesity- related 
conditions, for example, non- alcoholic fatty 
liver disease (NAFLD), as well as hepatitis C 
virus (HCV), and alcohol abuse,3 whereas in 
eastern Asia and sub- Saharan Africa hepatitis 
B virus (HBV) is more prevalent as an etio-
logical agent. Additional risk factors include 
diabetes mellitus, obesity, exposure to afla-
toxin B, hemachromatosis, and other heredi-
tary disorders.4 5
Although curative interventions such as 
liver transplant, surgery, and ablation may 
offer favorable outcomes for patients with 
early- stage HCC, for many years options 
were limited and prognosis was very poor 
for advanced disease.6–8 The 2007 approval 
of the multi- tyrosine kinase inhibitor (TKI), 
sorafenib, for the first- line treatment of 
advanced HCC represented a breakthrough 
as it was the first systemic therapy in several 
decades to demonstrate improved survival 
in liver cancer.9 However, despite several 
additional approvals for TKIs including rego-
rafenib10 and lenvantinib11 in the subsequent 
years,12 the new modalities only offered incre-
mental increases in overall survival (OS) for 
patients with advanced HCC, until the advent 
of immunotherapy and immune- based 
combination therapies.
In 2017, the US Food and Drug Adminis-
tration (FDA) granted the first approval for 
an immune checkpoint inhibitor (ICI) for 
HCC. Nivolumab (targeting programmed 
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cell death protein 1 [PD-1]) monotherapy received accel-
erated approval based on a significant response rate and 
prolonged duration of response (DOR) with manageable 
side effects in patients who had previously been treated 
with sorafenib.13 This was followed by encouraging data 
for other ICIs—pembrolizumab (another anti- PD-1 ICI) 
monotherapy14 and nivolumab in combination with the 
cytotoxic T lymphocyte antigen-4 (CTLA-4) antagonist 
ipilimumab15 —resulting in further accelerated approvals 
by the FDA. The confirmatory phase III studies for single- 
agent nivolumab and permbrolizumab, however, did not 
meet their end points. In 2020, the anti- programmed 
death- ligand 1 (PD- L1) antibody atezolizumab in combi-
nation with the anti- vascular endothelial growth factor 
(VEGF) antibody bevacizumab16 gained full FDA approval 
for first- line treatment of HCC on the basis of the phase III 
study IMbrave150. This was the first regimen to demon-
strate superiority to sorafenib in HCC since sorafenib’s 
approval in 2007, in addition to being the first immuno-
therapy plus anti- VEGF combination to gain approval for 
liver cancer. Additional trials are ongoing and the thera-
peutic landscape continues to evolve and expand.
HCC often develops on a background of chronic 
inflammation, metabolic stress, cirrhosis, or fibrosis, 
and thus, the use of immunotherapy in the setting of a 
compromised liver is a complex but common challenge. 
Although HCC is frequently an immunogenic cancer, 
characterized by tumor- infiltrating lymphocytes (TILs) 
in the tumor microenvironment, the intratumoral milieu 
has been shown to be generally immunosuppressive—in 
part due to the acquired immune dysfunction that occurs 
with cirrhosis, viral infection, or environmental insults 
that contribute to disease development, but also partially 
related to the liver’s intrinsic tolerogenicity.17 18 Despite 
these hurdles, the incorporation of immunotherapy into 
HCC care has offered more options to clinicians and has 
extended survival considerably for a subset of patients.
The approval of immunotherapy agents for the treat-
ment of HCC is relatively recent as compared with other 
malignancies and experience with these new therapies is 
still limited. Additionally, immunotherapy carries unique 
considerations in many clinical aspects including patient 
selection, management of immune- related adverse events 
(irAEs), and evaluation of response to therapy compared 
with other systemic treatments. To support the oncology 
community and provide evidence- and consensus- based 
recommendations on immunotherapy for HCC, the 
Society for Immunotherapy of Cancer (SITC) convened 
an international panel of experts to develop a new clin-
ical practice guideline (CPG), covering topics including 
recommended therapies, emerging agents, diagnostics 
and biomarkers, monitoring response to treatment, 
special patient populations, toxicity management, and 
quality of life (QOL). Although the guideline focuses on 
therapies approved by the FDA, the authors, as an inter-
national team, acknowledge that recommendations may 
not fully align with approval or reimbursement policies 
in other countries outside the US, and they encourage 
harmonization. The recommendations within this guide-
line are meant to complement rather than supplant 
sound clinical judgment, and their aim is to provide 
clinicians with the most current thinking on integrating 
immunotherapy into the treatment of patients with HCC.
GUIDELINE DEVELOPMENT METHODS
The Institute of Medicine’s (IOM) Standards for Devel-
oping Trustworthy Clinical Practice Guidelines were used 
as a model to develop the recommendations in this manu-
script. IOM standards dictate that guideline development 
is led by a multidisciplinary expert panel using a trans-
parent process where both funding sources and conflicts 
of interest are readily reported. This CPG is intended to 
provide guidance and is not a substitute for the profes-
sional judgment of individual treating physicians.
Conflict of interest management
As outlined by IOM standards, all financial relationships 
of expert panel members that might result in actual, 
potential, or perceived conflicts of interest were individ-
ually reported. Disclosures were made prior to the onset 
of manuscript development and updated on an annual 
basis. In addition, panel members were asked to articu-
late any actual or potential conflicts at all key decision 
points during guideline development, so that participants 
would understand all possible influences, biases, and/
or the diversity of perspectives on the panel. Although 
some degree of relationships with outside interests are 
to be expected among experts, panel candidates with 
significant financial connections that may compromise 
their ability to fairly weigh evidence (either actual or 
perceived) were not eligible to participate in guideline 
development.
Recognizing that guideline panel members are among 
the leading experts on the subject matter under consid-
eration and guideline recommendations should have 
the benefit of their expertize, any identified potential 
conflicts of interests were managed as outlined in SITC’s 
disclosure and conflict of interest resolution policies. 
As noted in these policies, panel members disclosing a 
real or perceived potential conflict of interest may be 
permitted to participate in consideration and decision- 
making of a matter related to that conflict, but only if 
deemed appropriate after discussion and agreement by 
the expert panel.
The financial support for the development of this 
guideline was provided solely by SITC. No commercial 
funding was received.
Recommendation development
Panel recommendations are based on literature evidence, 
where possible, and clinical experience, where appro-
priate.19 Consensus for the recommendations here was 
generated by open communication and scientific debate 
in small- group and whole- group settings, surveying and 
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responses to clinical questionnaires, as well as formal 
voting in consensus meetings.
For transparency, a draft of this CPG was made publicly 
available for comment during the development process 
and prior to publication. All comments were evaluated 
and considered for inclusion into the final manuscript 
according to the IOM standard.
Evidence rating
The evidence- and consensus- based recommendations 
of the panel were refined throughout the development 
process in order to obtain the highest possible agreement 
among the experts, however, the minimum threshold was 
defined as 75% approval among the voting members. 
Evidence supporting panel recommendations was graded 
according to the Oxford Centre for Evidence- Based Medi-
cine (OCEBM) Levels of Evidence Working Group ‘The 
Oxford Levels of Evidence 2’ (2016 version). A summary 
of the OCEBM grading scale may be found in table 1. 
The level of evidence (LE) for a given recommendation is 
expressed in parentheses following the recommendation 
(eg, LE: 1). Recommendations without an associated LE 
were based on expert consensus.
DIAGNOSTICS AND STAGING FOR PATIENTS WITH HCC
Initial HCC diagnosis
The initial diagnostic workup of HCC typically comprises 
a histologic analysis of tumor samples obtained by biopsy 
or surgery, cross- sectional imaging, a detailed analysis 
of the liver’s condition with laboratory studies, and an 
assessment of the potential etiology of the HCC including 
investigations of HBV and HCV viral status. Guidelines 
for surveillance screening, initial diagnosis, and staging 
of HCC have been developed by multiple organizations 
including, but not limited to, the American Association 
for the Study of Liver Diseases (AASLD),7 the American 
College of Gastroenterology (AGC),20 the European 
Society for Medical Oncology (ESMO),21 the European 
Association for the Study of the Liver (EASL)22 and the 
Japan Society of Hepatology (JSH).23 These organiza-
tions and others have also put forth guidelines for non- 
immunotherapeutic approaches for the treatment of 
HCC.
HCC may be identified using computerized tomog-
raphy (CT) and magnetic resonance imaging (MRI) 
with Liver Imaging Reporting And Data Systems (LI- 
RADS).24 The LI- RADS system provides a standardized 
approach for radiologists to communicate with the 
treating physicians and provides a certain level of confi-
dence that a lesion in a cirrhotic liver or a liver at risk for 
cirrhosis presents as HCC on imaging.25 LI- RADS staging 
ranges from LR-1, for lesions that are definitely benign, to 
LR-5, which represents 100% probability of being HCC. 
The LI- RADS system acknowledges that limitations exist, 
and has included an LR- NC (for non- categorizable) cate-
gory where diagnostic possibilities cannot be meaning-
fully narrowed. LI- RADS is endorsed by the AASLD,7 as 
well as by the Organ Procurement and Transplantation 
Network (OPTN)/United Network for Organ Sharing 
(UNOS). Contrast agents have also greatly enhanced the 
diagnostic accuracy of MRIs. Multiple meta- analyses have 
determined that gadolinium ethoxybenzyl diethylene-
triamine pentaacetic acid (Gd- EOB- DTPA)- enhanced 
MRI has superior sensitivity, specificity, and diagnostic 
odds ratio (OR) as compared with multidetector CT.26–28 
However, most published guidelines do not recommend 
one imaging modality over the other.
Patients with HCC often present with underlying 
cirrhosis—two conditions with independent mortality 
risks. It is essential for a care team comprised of multiple 
specialties, including perspectives from both hepatology 
and oncology, to be established early so that a treatment 
plan that addresses all of the complex needs of a patient 
with HCC may be developed.29 A multidisciplinary tumor 
board review of liver lesions is recommended for HCC 
diagnosis and management plans, particularly for patients 
with tumors that may be eligible for transplant, surgery, 
or liver- directed treatments.
Historically, avoiding tumor biopsy has been acceptable 
practice in patients with cirrhosis and imaging character-
istics consistent with HCC. One concern of performing 
biopsies in this disease has been the putative risk for 
tumor dissemination outside the liver via needle track 
seeding. The occurrence of needle track seeding appears 
to be uncommon in the published literature, however, 
with incidence rates estimated to be as low as 2.7% overall, 
or 0.9% per year.30 While biopsy may be less encouraged 
in certain clinical scenarios such as in patients where liver 
transplants are being considered, histologic diagnosis 
is increasingly encouraged for the diagnosis of HCC, 
particularly for more advanced tumors requiring systemic 
therapy. Other primary liver tumors such as cholangio-
carcinoma or mixed cholangiohepatoma can occasion-
ally present very similarly to HCC, and the treatment for 
these tumors can be distinct. Other entities such as meta-
static neuroendocrine cancers can similarly demonstrate 
Table 1 Summary of ‘The Oxford Levels of Evidence 2’ (Adapted from the OCEBM Levels of Evidence Working Group)
Level 1 Level 2 Level 3 Level 4 Level 5
Systematic review or 
meta- analysis




controlled cohort, or 
follow- up study
Case series, case- 




OCEBM, Oxford Centre for Evidence- Based Medicine.
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arterial enhancement on multiphase imaging.31 Addi-
tionally, in rare instances, tissue biopsy may uncover 
certain genetic alterations that render a patient eligible 
for a tissue- agnostic therapy or a clinical trial.
HCC staging
An ideal staging system in HCC serves two purposes: treat-
ment indication and prognostic prediction. A variety of 
staging systems have been developed, and their perfor-
mance and validation varies. While some staging systems 
focus on pathology, others incorporate radiological char-
acteristics, serum biomarkers, liver function, and perfor-
mance status. In most solid tumors, staging is performed 
at the time of surgery using resected specimens. The 
Tumor- Node- Metastases (TNM) classification, developed 
by the American Joint Committee on Cancer (AJCC), clas-
sifies the primary tumor (T) based on size, number, and 
vascular invasion.32 However, the TNM classification is not 
currently used to guide treatment for HCC. Also, impor-
tantly, the TNM classification should not be confused 
with the radiologic T- staging system used by LI- RADS and 
OPTN/UNOS, which is summarized in table 2.
Radiographic T- staging is of limited pretreatment prog-
nostic and predictive value for patients being consid-
ered for systemic therapy, as the system does not take 
into account liver function, which is an important risk 
factor for patients with HCC. Several alternative staging 
or scoring systems have been developed, including the 
Barcelona- Clinic Liver Cancer (BCLC) system,33 Cancer 
of the Liver Italian Program (CLIP),34 Japan Integrated 
Staging (JIS),35 Chinese University Prognostic Index 
(CUPI),36 Groupe d’Etude et de Traitement du Carci-
nome Hépatocellulaire (GETCH)37 plus many others.
The BCLC system, summarized in table 3, has gained 
wide recognition and has been endorsed by multiple 
international hepatology associations including AASLD6 
and EASL. Several large- scale cohort studies have vali-
dated the BCLC system, including in Korean patients 
with treatment‐naïve HCC,38 US patients,39 and Italian 
patients undergoing radical surgery.40 In addition, scoring 
by the BCLC system has been reported and studied in 
subgroup analyses for most of the phase III studies done 
in advanced HCC.
HCC is a highly heterogeneous disease with varied 
underlying etiologies depending on geography and 
demographics. Studies comparing the performance of 
staging systems for predicting prognosis have returned 
conflicting results depending on the patient population 
investigated and the treatments administered. The JIS 
score showed the best ability to predict OS by disease stage 
in an analysis of Japanese patients,41 whereas an analysis 
of 1,713 prospectively enrolled patients with HCC in 
Taiwan found that CLIP was the best prognostic model in 
patients undergoing both curative and non- curative treat-
ments.42 In the advanced and metastatic disease setting, 
another comparison of the prognostic value of different 
systems determined CLIP and CUPI to be the most reli-
able staging systems for patients with HCV and HBV etiol-
ogies, respectively.43 In these analyses of patients with 
advanced disease in need for systemic therapy, BCLC and 
TNM lacked prognostic value.
Liver function assessment is a critical component of 
HCC treatment that is required for every patient. Some 
of the staging systems embed within them the Child- Pugh 
classification, recognizing the need for assessing the 




1 One HCC <20 mm
2 One HCC ≥20 mm and ≤50 mm, or two or three 
HCCs, all ≤30 mm
3 One HCC >50 mm, or two or three HCCs, at least 
one >30 mm
4 4A. Four or more HCCs, regardless of size
4B. HCC + TIV
HCC, hepatocellular carcinoma; LI- RADS, Liver Imaging Reporting 
And Data System; OPTN/UNOS, Organ Procurement and 
Transplantation Network/United Network for Organ Sharing; TIV, 
tumor in vein.
Table 3 Barcelona- Clínic Liver Cancer (BCLC) 







































End- stage liver 
function
3 months
*The American Association for the Study of Liver Disease (AASLD) 
recommends including ECOG PS 0 to 1 in stage 0, A and B, 
because of the significant overlap between PS 0 and PS 1
BCLC, Barcelona- Clinic Liver Cancer; ECOG, Eastern Cooperative 
Oncology Group; PS, performance status.
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extent of liver functionality as part of the staging of the 
disease. The Child- Pugh score evolved over time from the 
original system built in 1973 to help assess for survival of 
patients with bleeding esophageal varices.44 Of note, in 
the original Pugh effort, none of the patients had HCC. 
The system evolved into a five- parameter staging system 
which consists of three laboratory values (serum albumin, 
bilirubin, and prothrombin levels) and two clinically 
assessed variables (presence and degree of ascites and 
hepatic encephalopathy). A final score ranging from 5 to 
15 is calculated based on the range of laboratory values 
and severity of clinical symptoms, and then classified into 
one of three classes: A (5–6), B (7–9), and C (10–15).44 45 
Median survival of untreated HCC has been shown to 
be approximately 2.5 times lower in patients with Child- 
Pugh B disease compared with those with Child‐Pugh 
A.46 Recently, however, the limitations and subjectivity 
involved in the grading of clinical variables have called 
into question Child- Pugh scores in assessing liver func-
tion in HCC.47
The albumin- bilirubin (ALBI) grade, a simpler model 
to assess liver function based only on serum albumin 
and bilirubin, has been validated in study cohorts 
from multiple geographic regions and multiple clin-
ical scenarios, including patients undergoing resec-
tion and sorafenib treatment. The score is calculated 
as (log10 bilirubin [µmol/L]×0.66) + (albumin [g/L] × 
−0.0852), leading to three possible grades: ALBI Score 
≤ −2.60 (ALBI grade 1), ALBI Score > −2.60 to ≤ −1.39 
(ALBI grade 2), and ALBI Score > −1.39 (ALBI grade 
3).48 The ALBI grade demonstrated superior prognostic 
value to the Child- Pugh score in a study of patients with 
HCC treated with radioembolization, particularly within 
patients with Child- Pugh A disease.49 ALBI grade also 
predicts OS after surgical resection (p<0.001), transarte-
rial chemoembolization (TACE) (p<0.001) and sorafenib 
treatment (p<0.001), with independent prognostic value 
across BCLC stages, geographic regions (p<0.001),50 and 
for cancers being treated with immunotherapy.50
Diagnostic biomarkers
Several biomarkers have been put forward to predict 
prognosis in HCC, yet none are currently routinely used 
to guide treatment decisions for patients being consid-
ered for immunotherapy. Serum alpha- fetoprotein (AFP) 
has been the most widely used marker to increase the 
suspicion for a diagnosis of HCC, and has been included 
in international guidelines.21 51 However, the value of 
AFP as a surveillance marker remains controversial,52 and 
establishing a threshold value to diagnose HCC remains 
a challenge.52 53 Tumor- derived AFP has also been impli-
cated in impaired dendritic cell function.54 Glypican 3 
(GPC3), an antigen that is highly expressed on tumor 
cells and minimally present on healthy tissues,55 has been 
proposed as a serum biomarker for HCC and is being 
pursued as a target for chimeric antigen receptor (CAR) 
T cell therapies.56 However, neither AFP nor GPC3 have 
demonstrated predictive power for patients being treated 
with ICIs, although this is an active area of research.
The GALAD score, which determines risk of HCC based 
on patient sex, age, and serum levels of AFP, AFP isoform L3, 
and des- gamma- carboxy prothrombin has been validated 
for detection of HCC in patients with non- alcoholic steato-
hepatitis (NASH) with and without cirrhosis.57 A combi-
nation of GALAD and ultrasound (GALADUS) score has 
been shown to further improve performance, with an area 
under the curve of 0.98 (95% CI 0.96 to 0.99; cut- off −0.18; 
sensitivity 95%; specificity 91%) in a single- center cohort 
of 111 patients with HCC and 180 controls with cirrhosis or 
chronic HBV.58 In March of 2020, the FDA granted break-
through device designation to the Elecsys GALAD score 
to aid in early diagnosis of HCC (for further discussion 
of immunotherapy- specific biomarkers, including PD- L1 
status, see the Patient selection and management section).
Panel recommendations
 ► A multidisciplinary tumor board review of liver lesions 
is recommended for HCC diagnosis and the develop-
ment of a management plan.
 ► Notwithstanding that LI- RADS-5 is nearly 100% 
specific for HCC (LE: 1), histologic confirmation is 
recommended for patients with unresectable disease 
particularly prior to the initiation of systemic therapy. 
Histologic diagnosis is mandatory for non- cirrhotic 
patients.
 ► Despite the controversy regarding the scoring and 
staging systems that could be used, before initiation 
of systemic therapy, an evaluation of liver function, 
including aspartate transaminase (AST)/alanine 
aminotransferase (ALT), bilirubin, prothrombin time 
(PT)/international normalized ratio (INR), albumin, 
plus platelets, is critical (LE: 2).
 ► For patients being considered for immunotherapy, an 
HCC- specific staging system incorporating liver func-
tion assessment is suggested (LE: 2).
 ► To evaluate patients prior to receiving immuno-
therapy, Child- Pugh classification would be the most 
appropriate to date (LE: 1) to measure liver function.
RECOMMENDED IMMUNOTHERAPIES FOR HCC
Available agents and indications
For more than 10 years, sorafenib was the only systemic 
therapy approved by the FDA for the treatment of HCC. 
Since 2017, four ICI regimens have entered the clinic 
after having received full or accelerated approval by 
the FDA for the treatment of advanced HCC. Only one 
combination, atezolizumab with bevacizumab, had full 
FDA approval at the time of guideline preparation, the 
remaining regimens (nivolumab and pembrolizumab 
monotherapy and nivolumab with ipilimumab) received 
accelerated approvals, and FDA review of confirmatory 
trials is ongoing. Results of the landmark trials leading to 
these approvals are described in table 4. Further details 
for each indication are discussed in chronological order 
of their FDA approvals.
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Prior sorafenib therapy
In 2017, nivolumab received accelerated approval as 
monotherapy for the treatment of patients with HCC 
with progression following or intolerance to sorafenib. 
Approval was based on data from a cohort of patients 
from the CheckMate 040 Trial, a phase I/II, open- label, 
multicenter study. Among the 154 patients treated with 
nivolumab, 22 (14.3%; 95% CI 9.2% to 20.8%) had an 
objective radiologic response based on Response Eval-
uation Criteria in Solid Tumors (RECIST) v1.1 criteria. 
Three patients (1.9%) had complete responses (CRs) 
and 19 (12.3%) had partial responses (PRs). DORs 
ranged from 3.2 months to 38.2+ months with 91% 
lasting 6 months or longer and 55% lasting 12 months 
or longer. The overall response rate (ORR), based on 
modified RECIST (mRECIST), was 18.2% (28 patients; 
95% CI 12.4% to 25.2%) and the CR rate was 3.2% 
(5 patients) with a PR rate of 14.9% (23 patients). No 
differences in response rates were observed across PD- L1 
expression levels.13 Postregistration studies support the 
safety of single- agent nivolumab in patients with Child- 
Pugh B disease59 where treatment is associated with 
shorter OS compared with Child- Pugh A disease (7.3 
months vs 16.3 months; p<0.001).60 Data from cohort 5 
of CheckMate 040, which included 25 sorafenib- naïve 
and 24 sorafenib- treated patients with Child- Pugh B7- B8 
advanced HCC, also showed safety and efficacy for single- 
agent nivolumab in a setting of mild to moderate liver 
impairment61 (for further details on immunotherapy in 
special patient populations, see the Patient selection and 
management section). Continued accelerated approval 
for nivolumab monotherapy was contingent on the 
confirmatory trial CheckMate 459 (described below).
On March 10, 2020, nivolumab in combination with 
ipilimumab received accelerated approval by the FDA 
to treat patients with HCC who were previously treated 
with sorafenib. Approval was based on the results of an 
additional cohort (cohort 415) from CheckMate 040. In 
the CheckMate 040 cohort 4, 148 patients were random-
ized 1:1:1 to three different treatment arms to evaluate 
different dosing regimens of the combination: high- 
dose ipilimumab, low- dose ipilimumab and continuous 
nivolumab/ipilimumab for arms A, B, and C, respectively. 
For approval, efficacy was evaluated in the 49 patients 
who received nivolumab at 1 mg/kg and ipilimumab at 
3 mg/kg every 3 weeks for 4 doses, followed by single- 
agent nivolumab every 2 weeks until disease progression 
or unacceptable toxicity. Data from all arms support 
anti- HCC activity of the regimen, however. The ORR 
reported for accelerated approval was 33% (n=16; 95% CI 
Table 4 Landmark trials leading to FDA approvals for immunotherapy for HCC
Trial (NCT#) Phase Agent(s) evaluated Study population Patients Outcomes
CheckMate 040
(NCT01658878)
I/II Nivolumab*† Patients with histologically 
confirmed advanced HCC 
with or without HCV or 
HBV infection. Previous 
sorafenib treatment was 
allowed. CP A or B7 
disease for dose escalation; 
CP A disease for dose 
expansion.
262 ORR 20%




(95% CI 6% to 28%) in 
population with progressive 




I Pembrolizumab* Patients with disease 
progression on or after 
sorafenib or intolerant to 
sorafenib, and measurable 
CP A disease.
104 ORR 17%
(95% CI 11% to 26%)
CheckMate 040
(NCT01658878)
I/II Nivolumab+ipilimumab* Patients with histologically 
confirmed advanced HCC 
with or without HCV or 
HBV infection. Previous 
sorafenib treatment was 
allowed.
148 ORR 33%
(95% CI 20% to 48%)
IMbrave150‡ III Atezolizumab+
bevacizumab vs sorafenib
Patients with unresectable 
HCC who had received no 
prior systemic therapy and 
had well- compensated liver 
disease.
501 OS HR 0.58 (95% CI 0.42 
to 0.79; p<0.001)
 
ORR 27.3% vs 11.9% 
(p<0.001)
*Accelerated approval contingent on confirmatory trials
†Indication voluntarily withdrawn July 2021
‡Updated data with 12 additional months of follow- up found ORR of 29.8% (95% CI 24.8% to 35.0%) for atezolizumab+bevacizumab versus 11.3% 
(95% CI 6.9% to 17.3%) for sorafenib66
CI, confidence interval; CP, Child- Pugh; FDA, US Food and Drug Administration; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, 
hepatitis C virus; HR, hazard ratio; ORR, overall response rate; OS, overall survival.
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20% to 48%), with 4 CRs and 12 PRs. DORs ranged from 
4.6 months to 30.5+ months, with 31% of responses lasting 
24 months or longer.62 An updated analysis at a minimum 
follow- up of 44 months found ORRs by blinded indepen-
dent central review of 32%, 31%, and 31% for arms A, 
B, and C, respectively. Median DORs were 17.5 months, 
22.2 months, and 16.6 months for arms A, B, and C, and 
median OS for each arm was 22.2 months, 12.5 months, 
and 12.7 months, respectively.63
In CheckMate 459, a phase III trial evaluating the 
efficacy of nivolumab as a first- line monotherapy, the 
ORR was 15% in the nivolumab group and 7% in the 
group receiving sorafenib. Median OS was 16.4 months 
for nivolumab- treated patients and 14.7 months for 
sorafenib- treated patients (HR 0.85; 95% CI 0.72 to 1.02; 
p=0.0752). The difference in OS between the two groups 
did not meet prespecified thresholds for statistical signif-
icance (HR 0.84; p=0.0419).64 Nevertheless, nivolumab 
demonstrated a favorable safety profile, better response 
rate, improved tolerability, and better QOL outcomes 
when compared with sorafenib. A trend towards better 
survival and response rate was noted in patients with 
PD- L1 tumor proportion score (TPS) ≥1% (about 19% of 
the randomized subjects) measured by the Dako PD- L1 
immunohistochemistry (IHC) assay, supporting the 
importance of predictive biomarker development. In a 
4:5 vote, the FDA Oncologic Drugs Advisory Committee 
(ODAC) recommended rescinding the indication for 
nivolumab for the treatment of patients with HCC and 
prior sorafenib therapy. There was unanimous agreement 
from committee members that voting was difficult due to 
the many factors, including the earlier vote to maintain 
the indication for pembrolizumab monotherapy. Those 
in favor of continued accelerated approval for nivolumab 
in this patient population highlighted the unmet need 
for second- line options. Rationale against continuing the 
indication centered on the lack of OS benefit in Check-
Mate 459 and the inadequacy of the proposed alterna-
tive studies to generate satisfactory evidence for efficacy 
in the second- line setting. Discussion also narrowed in 
on whether data exist to recommend nivolumab mono-
therapy over an ipilimumab plus nivolumab combina-
tion regimen, including debate over whether the group 
of patients deemed unfit for the dual checkpoint inhib-
itor combination represent a new indication that was not 
formally defined nor evaluated in trials to date. In July 
2021, the nivolumab monotherapy indication for HCC 
was voluntarily withdrawn.
Accelerated approval was granted to pembrolizumab in 
2018 for patients with HCC who have previously received 
sorafenib based on results from the phase II KEYNOTE-
224 Trial. The study enrolled 104 patients to receive 
single- agent pembrolizumab with advanced HCC and 
radiographic progression or intolerance to sorafenib. 
The ORR was 17% (95% CI 11% to 26%) and among the 
18 patients who responded, there was 1 CR and 17 PRs. At 
data cut- off, 12 of the 18 responses were ongoing and the 
median DOR was not reached (range 3.1–14.6+ months). 
Of the responders, 89% had a DOR ≥6 months, and 56% 
had a DOR ≥12 months.14
The phase III KEYNOTE-240 confirmatory trial evalu-
ating pembrolizumab versus placebo was negative based 
on the co- primary end point of median OS and PFS. 
Median OS was 13.9 months (95% CI 11.6 to 16.0) for 
pembrolizumab versus 10.6 months (95% CI 8.3 to 13.5) 
for placebo (HR 0.781; 95% CI 0.611 to 0.998; p=0.0238), 
and median PFS for pembrolizumab was 3.0 months 
(95% CI 2.8 to 4.1) versus 2.8 months (95% CI 1.6 to 
3.0; HR 0.718; 95% CI 0.570 to 0.904; p=0.0022), but this 
did not meet statistical significance by the prespecified 
statistical plan.65 The study did confirm the single- agent 
response rate of pembrolizumab in this setting with an 
ORR of 18.3 (95% CI 14.0 to 23.4) and a DOR of 13.8 
months (range 1.5–23.6+ months). Despite the confirma-
tory trial not meeting prespecified end points, when the 
FDA ODAC reviewed the accelerated approval in April 
2021 the vote to maintain the indication for pembroli-
zumab was unanimous, citing unmet medical need for 
patients who cannot receive first- line atezolizumab with 
bevacizumab (described below) and who have disease 
progression with or become intolerant to TKIs.
First-line therapy
The first ICI regimen to receive full approval and the 
first to receive first- line approval for the treatment of 
HCC is atezolizumab in combination with bevacizumab 
for patients who have not received prior systemic therapy, 
which was approved in 2020. Approval was based on the 
global, open- label, phase III IMbrave150 trial, in which 501 
patients with unresectable HCC were randomly assigned 
in a 2:1 ratio to receive either first- line atezolizumab plus 
bevacizumab or sorafenib monotherapy until unaccept-
able toxic effects or loss of clinical benefit occurred. At 
the primary analysis, the HR for death with atezolizumab 
plus bevacizumab compared with sorafenib was 0.58 
(95% CI 0.42 to 0.79; p<0.001). The 12- month OS rate 
was 67.2% (95% CI 61.3% to 73.1%) with atezolizumab 
plus bevacizumab and 54.6% (95% CI 45.2% to 64.0%) 
with sorafenib. Median PFS was 6.8 months (95% CI 5.7 
to 8.3) versus 4.3 months (95% CI 4.0 to 5.6) with atezoli-
zumab plus bevacizumab versus sorafenib, respectively 
(HR for disease progression or death 0.59; 95% CI 0.47 
to 0.76; p<0.001).16 In an updated post hoc survival anal-
yses, median OS was 19.2 months with atezolizumab plus 
bevacizumab compared with 13.4 months with sorafenib 
(HR 0.66; 95% CI 0.52 to 0.85; p=0.0009). The OS rates 
at 18 months were 52% vs 40% with atezolizumab plus 
bevacizumab versus sorafenib, respectively.66
The combination therapy also delayed deterioration 
in QOL compared with sorafenib monotherapy. In terms 
of the tolerability profile, grade 3–4 adverse events (AEs) 
occurred in 57% of patients treated with atezolizumab 
with bevacizumab.16 Additionally, the development of 
anti- drug antibodies (ADAs) is a possibility in patients 
treated with atezolizumab.67 In IMbrave150, among 318 
ADA- evaluable patients with HCC, 30% (n=94) tested 
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positive for treatment- emergent ADAs at one or more 
post- dose time points. In exploratory adjusted analyses, 
patients who were ADA- positive at landmark week 6 had 
a similar OS with atezolizumab plus bevacizumab versus 
sorafenib, whereas those with ADA- negative status had an 
improved OS compared with sorafenib. However, similar 
PFS and ORR benefit was seen with the combination over 
sorafenib regardless of ADA status.68
Panel recommendations
 ► For first- line treatment of patients with advanced 
Child- Pugh A HCC, atezolizumab plus bevacizumab is 
recommended, unless either medication is contrain-
dicated (LE: 2).
 ► General contraindications to bevacizumab include 
high risk of cardiac disease, stroke, hemorrhage, 
hemoptysis, gastrointestinal perforation, or non- 
healing wounds (LE: 1). (For contraindications 
to immunotherapy, see the Patient selection and 
management section). Consideration should be given 
to timing of prior events. Additional contraindica-
tions specifically relevant to HCC include untreated 
or incompletely treated gastroesophageal varices at 
risk for bleeding (LE: 2).
 ► For patients with contraindications to atezolizumab 
plus bevacizumab treatment, lenvatinib or sorafenib 
should be considered as standard first- line therapy 
(LE: 2).
 ► Nivolumab monotherapy has demonstrated activity in 
Child- Pugh B7- B8 HCC for both first- line treatment 
of sorafenib- naïve patients and for second- line treat-
ment of patients who were intolerant to or progressed 
on sorafenib (LE: 3).
 ► For patients with good performance status who have 
progressed on first- line therapy and have not received 
prior immunotherapy, other non FDA- approved or 
conditionally approved anti- PD-1 checkpoint inhib-
itors may be considered as immunotherapeutic 
options (LE: 3).
IMMUNOTHERAPIES IN DEVELOPMENT FOR HCC
The potential benefit of ICIs as monotherapies or in 
combination regimens including other ICIs or anti- 
VEGF agents for advanced HCC is being evaluated in 
several ongoing trials. Additionally, mechanistic ratio-
nale supports the integration of ICIs with locoregional 
therapies for disease in early stages, and some studies 
have reported tolerable safety with evidence for efficacy 
with the combination of checkpoint blockade and liver- 
directed therapy. Finally, the development of novel strate-
gies such as vaccines or adoptive cell therapies is an active 
area of investigation, although still in early stages at the 
time of publication.
Checkpoint inhibitors and novel combinations
Tremelimumab, an anti- CTLA-4 ICI, has been evaluated 
in a pilot trial of patients with HCC with chronic HCV 
infection. Among the 17 patients who were assessable 
for tumor response, the PR rate was 17.6% and disease 
control rate (DCR) was 76.4% with a median time to 
progression of 6.48 months (95% CI 3.95 to 9.14). Signif-
icant drops in viral load were observed in the 20 patients 
who were evaluable for toxicity and viral responses, and 
no patients needed steroids because of severe irAEs.69 
Single- agent tislelizumab (anti- PD-1),70 camrelizumab 
(anti- PD-1),71 and durvalumab (anti- PD- L1)72 are all also 
being studied in phase III trials.
Combination ICI regimens are also under investiga-
tion. The FDA has approved nivolumab at 1 mg/kg with 
ipilimumab at 3 mg/kg regimen as a second- line treat-
ment option for patients with prior sorafenib exposure.73 
Recently, another combination regimen, durvalumab in 
combination with tremelimumab, reported an ORR of 
up to 22.7% and a median OS of up to 18.7 months in 
the advanced HCC population using one single dose of 
tremelimumab at 300 mg, with further enhancement of 
response among patients with CD8+ Ki67+ proliferative T 
cells.74 The phase III HIMALAYA trial investigating one 
single dose of tremelimumab with durvalumab as first- line 
treatment in patients with unresectable HCC is ongoing75 
and this combination regimen has been granted orphan 
drug designation by the FDA.
In the CheckMate 040 trial cohort 6,76 the efficacy and 
safety profile of the triplet combination of cabozantinib, 
nivolumab, and ipilimumab were analyzed and compared 
with the cabozantinib plus nivolumab doublet. A total 
of 71 sorafenib- naïve or sorafenib- experienced patients 
with advanced HCC were randomized to either receive 
nivolumab 240 mg every 2 weeks with cabozantinib 
40 mg daily (n=36) or nivolumab 3 mg/kg every 2 weeks 
with ipilimumab 1 mg/kg every 6 weeks and cabozan-
tinib 40 mg daily (n=35). Although the study was not 
powered to directly compare efficacy of the triplet versus 
doublet regimens, numerically higher response rates 
(29% vs 19%), better PFS (median 6.8 vs 5.4 months) 
and improved median OS (not reached vs 21.5 months; 
15- month OS rates: 70% vs 64%) were observed with the 
three- drug combination. Nevertheless, a higher rate of 
treatment- emergent AEs was also observed in the triplet 
arm, without the emergence of new safety signals in either 
treatment arms.
HCC is one of the most vascularized solid tumors and 
anti- angiogenic agents may complement immunother-
apies. Multiple anti- angiogenic multikinase inhibitors 
are being evaluated in combination with checkpoint 
inhibitors for HCC. The combination with the most 
available data at the time of manuscript preparation is 
pembrolizumab plus lenvatinib. In Study 116, an ongoing 
phase Ib multicenter open- label study of lenvatinib plus 
pembrolizumab in 104 patients with unresectable HCC, 
the confirmed ORRs at data cut- off were 46.0% (95% 
CI 36.0% to 56.3%) by mRECIST and 36.0% (95% CI 
26.6% to 46.2%) by RECIST v1.1 with median DORs 
of 8.6 months (95% CI 6.9 to not estimable [NE]) and 
12.6 months (95% CI 6.9 to NE), respectively. Median 
OS was 22 months and treatment- related AEs of grade 
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≥3 occurred in 67% of patients.77 The ongoing phase 
III LEAP‐002 trial is also studying the combination and 
enrolling patients for treatment with pembrolizumab 
plus lenvatinib for first- line treatment of advanced HCC.78 
Other ICI/TKI combination studies include avelumab 
with axitinib, which led to tumor shrinkage in 15 (68.2%) 
and 16 (72.7%) patients and an ORR of 13.6% (95% CI 
2.9% to 34.9%) and 31.8% (95% CI 13.9% to 54.9%) 
by RECIST and mRECIST, respectively in one study.79 
Cabozantinib is being combined with atezolizumab for 
patients who have not received prior systemic therapy for 
HCC in the phase III study COSMIC‐312.80
Integration with local and regional therapies
Locoregional therapies such as TACE and drug- eluting 
bead TACE (DEB- TACE) may induce immunogenic 
cell death, thus promoting CD8+ T cell infiltration into 
the tumor microenvironment, potentially synergizing 
with anti- PD- (L)1 therapy.81 Doxorubicin, which has 
been shown to cause immunogenic cell death,82 is the 
most commonly administered drug during TACE and 
DEB- TACE, and patients undergoing chemoemboliza-
tion have been shown to develop AFP- specific CD4+ T 
cell responses83 as well as GPC3- specific cytotoxic T cell 
responses.84
A few studies have reported tolerable safety and initial 
efficacy outcomes with the combination of ICIs and 
locoregional therapies such as TACE and radiofrequency 
ablation (RFA). One trial enrolled 32 patients with HCC 
for tremelimumab therapy at two dose levels (3.5 mg/
kg and 10 mg/kg intravenous [IV]) every 4 weeks for 
6 doses, followed by infusions every 3 months until off- 
treatment criteria were met. On day 36, patients under-
went subtotal RFA or chemoablation. Of the 19 evaluable 
patients, 5 (26.3%; 95% CI 9.1% to 51.2%) achieved PR. 
The median time to tumor progression was 7.4 months 
(95% CI 4.7 to 19.4) and median OS was 12.3 months 
(95% CI 9.3 to 15.4).85
Integration with transplant
Checkpoint inhibitors are considered contraindicated in 
patients undergoing transplantation due to fears of graft 
rejection.86 Reports have emerged of immunotherapy 
being used as salvage therapy in liver transplant recipi-
ents with malignancies other than HCC, but rejection was 
frequent. A review of 14 cases of liver transplant recipients 
who were treated with ICIs identified four cases of liver 
graft rejection and three cases with lethal outcomes.87 
Another retrospective study including 39 patients with 
solid organ transplants reported permanent discontinu-
ation of ICIs in 31% because of allograft rejection. Graft 
loss occurred in 81%, leading to death in 46%.88
Vaccines
Some vaccines have demonstrated manageable safety and 
preliminary efficacy in early phase trials in HCC. Although 
no antitumor effects or immune responses were detected 
among 40 patients with advanced HCC who were treated 
with low- dose cyclophosphamide in combination with a 
telomerase peptide vaccine (GV1001),89 other strategies 
have posted more promising results.
Several groups have attempted to develop peptide 
vaccines based on GPC3. One GPC3 peptide vaccine was 
well tolerated in a phase I trial that included 33 patients 
with advanced HCC. Vaccination induced a GPC3- specific 
cytotoxic T lymphocyte response in 90% of patients—
there was 1 PR and 19 cases of stable disease at 2 months.90 
That same vaccine was shown to lead to numerically lower 
rates of recurrence compared with surgery alone at 1 year 
(28.6% vs 54.3%) and 2 years (39.4% vs 54.5%) in the 
adjuvant setting in a phase II trial of 35 patients with HCC 
who had undergone resection.91
AFP- based vaccines have been shown to elicit T cell 
responses in early trials. Four immunodominant, human 
leukocyte antigen (HLA)- A*0201- restricted epitopes of 
AFP that are recognized by the human T cell repertoire 
have been identified.92 In a pilot phase I clinical trial that 
enrolled six HLA- A*0201 patients with AFP- positive HCC 
for intradermal vaccinations with the four peptides emul-
sified in incomplete Freund’s adjuvant, T cell responses 
were observed against most or all of the epitopes.93 Subse-
quently, a phase I/II trial that included 10 HLA- A*0201 
patients with AFP- positive HCC who were immunized with 
intradermal vaccinations of the four AFP peptides pulsed 
onto autologous dendritic cells found statistically signifi-
cant levels of AFP- specific T cells to at least one peptide 
by major histocompatibility complex (MHC) tetramer in 
60% of participants.94
Tumor lysate- based vaccines have also been evaluated 
in HCC. One study found that autologous tumor vacci-
nation significantly delayed time to recurrence in 60 
patients with HCC who had undergone curative resec-
tion. The 1- year, 2- year and 3- year recurrence rates in the 
30 patients in the vaccine group were 16.7%, 29.2%, and 
33.3%, respectively, compared with 30.8%, 53.8%, and 
61.5%, respectively, in the control group.95 Another phase 
II trial of autologous dendritic cells pulsed with tumor 
lysate observed a radiologically determined DCR of 28% 
in 35 patients with advanced HCC.96 Hepcortespenlisi-
mut- L, a tableted oral formulation derived from a heat- 
inactivated pooled blood of patients with HCC and viral 
hepatitis, has entered phase III trials in patients with 
HCC and demonstrated clear improvements in ALT, AST, 
alkaline phosphatase, and bilirubin levels compared with 
placebo.97
The dramatically high efficacy rates seen with RNA- 
based vaccines during the COVID-19 pandemic has re- in-
vigorated the study of RNA- vaccinology—a concept with 
roots in the immunotherapy discipline.98 99 RNA has been 
used as both a vaccine platform and an adjuvant to boost 
immunogenicity for HCC- specific epitopes, such as HLA- 
A*02- restricted tumor- associated peptides.100 101
Adoptive cell therapies
To date, the most advanced clinical studies for cellular 
therapies in HCC are with cytokine- induced killer cells 
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(CIKs), which are characterized by coexpression of CD3 
and CD56 and can be generated by expanding human 
peripheral blood mononuclear cells in the presence of 
interferon- gamma (IFNγ).102 103 One randomized phase 
III trial of CIKs as adjuvant therapy for patients with 
HCC undergoing resection demonstrated a median 
recurrence- free survival (RFS) of 44 months in the cell 
therapy group and 30 months in the control group (HR 
0.63; 95% CI 0.43 to 0.94; p=0.010 by one- sided log- rank 
test).104 A meta- analysis of 13 phase II and phase III trials 
involving CIKs for HCC that included a total of 1,212 
patients found that cellular therapy was associated with 
a significantly improved 1- year survival (OR 0.25; 95% CI 
0.12 to 0.52; p<0.001) and 2- year survival (OR 0.17; 
95% CI 0.07 to 0.43; p<0.001), as well as a favorable DCR 
(OR 0.09; 95% CI 0.04 to 0.25; p<0.001) and ORR (OR 
0.21; 95% CI 0.13 to 0.35; p<0.001).105
Allogenic natural killer (NK) cell- based adoptive ther-
apies have also been evaluated in HCC. One study that 
included 40 patients with stage IV HCC found that NK 
cell therapy synergized with irreversible electroporation 
(IRE), leading to decreased AFP expression and higher 
median OS compared with IRE alone (10.1 months vs 
8.9 months; p=0.0078).106 Allogenic NK cell therapy also 
showed synergy with cryoablation in a study that included 
61 patients with advanced HCC. After a median follow- up 
of 8.7 months (range 3.9–15.1 months), median PFS and 
DCR were higher among the 35 patients who received 
cryoablation plus NK cells compared with the 26 patients 
treated with cryoablation alone (PFS 9.1 months vs 7.6 
months; p=0.0107; DCR 85.7% vs 69.2%; p<0.01).107
Panel recommendations
 ► Clinicians should encourage patients' participation in 
clinical trials.
 ► Future biomarker development might help to select 
a subgroup of patients benefitting from single- agent 
nivolumab treatment. Designing a biomarker strategy 
based on pretreatment and on- treatment tissue and 
blood samples to assess immune cell changes and 
other correlatives is critical to elucidate mechanisms 
of response or resistance to immunotherapy in combi-
nation with local therapy in early- stage HCC.
 ► Studies evaluating combinations of other immuno-
therapies with ICIs should be based on solid scientific 
rationale.
 ► Future randomized studies to compare local therapy 
alone to local therapy combined with immuno-
therapy are essential to assess the expected synergy 
and favorable treatment outcome of the combination 
strategy.
PATIENT SELECTION AND MANAGEMENT
Patient selection
In selecting the appropriate patient for consideration 
of treatment with a standard immunotherapy- based 
approach (as opposed to within the context of a clinical 
trial), there are both general oncologic considerations 
as well as HCC- specific or liver- specific considerations. It 
is critical to account for the singular nature of HCC, as 
it generally arises in a damaged and potentially dysfunc-
tional liver. As many as 43% of patients with HCC will die 
as a direct result of cirrhosis as opposed to cancer progres-
sion.108 Therefore, clinical trials needed for patients with 
more advanced liver function decompensation than 
Child- Pugh B7 are encouraged, especially when the main 
factor behind liver function deterioration is HCC progres-
sion rather than the underlying liver disease. Additional 
considerations include the patient’s performance status 
and history of comorbidities, in particular the presence of 
any known autoimmune disorders. A patient’s eligibility 
for treatment with anti- VEGF therapy—either with TKIs 
(eg, sorafenib) or monoclonal antibodies (eg, bevaci-
zumab)—will also inform a treatment plan. Liver- specific 
factors that need to be considered include the stage of 
the HCC and the indication for treatment, the under-
lying synthetic liver function, and disease etiology and 
its bearing—if any—on outcome. There are also certain 
specific situations such as recurrence in the setting of 
liver transplant that need further study, as well as the role 
of biomarkers in predicting efficacy or toxicity. For many 
of these considerations, the data are varied in terms of the 
weight of evidence, which should be taken into account 
in regard to the degree to which they should influence 
the physician’s decision.
General considerations
Clinical trials demonstrating efficacy for immunotherapy 
have largely been performed in patient populations 
who were required to have a good performance status 
(ie, Eastern Cooperative Oncology Group (ECOG) 0 
to 1) in order to take part. This, of course, is a general 
and widely accepted principle of oncology trials which 
also applies to immunotherapy treatment, although 
two meta- analyses have demonstrated no significant 
differences in OS between patients stratified by perfor-
mance status between the groups with ECOG 0 and with 
ECOG 1–2.109 110 The efficacy and tolerability of immu-
notherapy in patients with a performance status of >2 is 
largely unknown. Another population that is frequently 
excluded from trials and sometimes undertreated due 
to concerns about frailty is the elderly. Subgroup anal-
yses from IMbrave150, however, found that the safety 
of atezolizumab in combination with bevacizumab was 
largely identical between elderly (aged ≥65 years) and 
non- elderly (aged <65 years) patients. Furthermore, clin-
ical benefit with atezolizumab in combination with beva-
cizumab compared with sorafenib was confirmed, with 
elderly patients having similarly improved OS, PFS, and 
ORR as non- elderly patients.111
Cardiovascular toxicity risk is a major consideration 
if anti- VEGF therapy is being considered as part of the 
treatment plan for a patient with HCC. Anti- VEGF ther-
apies are associated with increased bleeding risk, which 
is an important consideration in this patient population, 
many of whom will have portal hypertension. Awareness 
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of contraindications to anti- VEGF therapy is important, 
particularly as these agents become further incorporated 
into evolving immune- based standards of care. A recent 
analysis found that as many as 35% of patients with cancer 
receiving bevacizumab were treated despite the presence 
of contraindicating comorbidities.112
HCC is often diagnosed at an advanced stage in patients 
living with HIV, and the hepatotoxicity of highly active 
antiretroviral drugs may further exacerbate underlying 
liver damage.113 114 Historically, patients with HIV have 
been excluded from trials, leading to an unmet need 
for effective therapies in this population—a group that 
also has poorer outcomes in HCC, specifically, compared 
with HIV- negative individuals.115 Although not yet studied 
specifically in HCC, tolerable safety and efficacy with ICI 
therapy for a variety of solid tumors has been demon-
strated for patients living with HIV.116 117
Patients with a history of autoimmune disorders have 
also historically been excluded from immunotherapy 
clinical trials given the mechanisms of action of immu-
notherapy agents and the risk of exacerbating existing 
autoimmunity. At present, the evidence for safety of ICIs 
in patients with pre- existing autoimmunity is limited to 
retrospective studies and case reports,118 which likely are 
not generalizable. Although one meta- analysis found that 
flares and irAEs in patients with autoimmune diseases 
treated with ICIs could often be managed, some events 
were severe and fatal. The overall incidence, however, 
could not be determined due to a lack of prospective 
studies.119 In addition, several studies have shown worse 
outcomes after ICI therapy among patients who were 
already taking steroids or immunosuppressive medica-
tion at baseline.120 121
Finally, racial and ethnic minorities have been reported 
to have higher rates of mortality from HCC in the USA.122 
Minority groups also have a history of underrepresenta-
tion in clinical trials,123 meaning that often these patients 
not only often lack access to the best care for their disease 
but also that clinicians must extrapolate from data on 
the majority population for decision- making due to lack 
of direct evidence for efficacy.124 Awareness of historical 
disparities and efforts to include diverse populations in 
future studies is important to improve outcomes for all 
patients.
HCC-specific considerations
At present, the data in support of immunotherapy for 
HCC apply to patient populations who are not amenable 
to curative approaches for early- stage disease such as 
resection, ablation, transplantation, or locoregional 
approaches for intermediate- stage disease (see Immuno-
therapies in development for HCC section for a discussion 
of integration of immunotherapy with these approaches). 
While immunotherapy for HCC in the neoadjuvant 
setting cannot be recommended at this time, studies are 
ongoing that will evaluate the safety and feasibility of 
immunotherapy in the neoadjuvant or postoperative/
ablation setting. Encouraging results were reported in 
the final analysis of a phase II study evaluating nivolumab 
alone or nivolumab with ipilimumab as neoadjuvant 
therapy with an overall pathologic CR rate of 24% among 
21 evaluable patients (2 patients in the nivolumab mono-
therapy group and 3 in the nivolumab plus ipilimumab 
group). Grade 3 toxicity was experienced by five patients 
receiving nivolumab plus ipilimumab and one receiving 
nivolumab monotherapy, and no grade ≥4 toxicity was 
reported.125 The phase Ib PRIME- HCC trial will also 
assess safety and bioactivity of preresection nivolumab 
with ipilimumab in patients with HCC.126 Additionally, the 
combination of neoadjuvant nivolumab and cabozatinib 
has been evaluated in an open- label, single- arm, phase 
I study in patients with borderline resectable or locally 
advanced HCC. Among the 12 patients who underwent 
successful surgical resection, 41.7% (n=5) had a major or 
complete pathologic response with 80% of the pathologic 
responders (n=4) remaining recurrence- free at a median 
follow- up of 1 year. Resection specimens from patients 
with responsive disease showed evidence for enrichment 
of IFNγ+ effector memory CD4+ T cells as well as granzyme 
B+ effector CD8+ T cells.127
HBV infection is the etiological agent for as much as 
50% of the incidence of HCC worldwide,128 and HCV 
is estimated to account for up to one- third of cases.129 
HCV- associated advanced HCC was the first setting in 
which ICIs were evaluated, although modest response 
rates and a median time to progression of 6.4 months 
were observed in the initial study’s 21- patient cohort 
treated with tremelimumab.69 Adequate viral control 
was reported in hepatitis- infected, ICI- treated patients in 
CheckMate 040 and KEYNOTE-224, and no worsening 
of hepatitis was observed.13 14 Published trials, however, 
required patients with HBV infections to be on antiviral 
therapy. Another retrospective study of outcomes among 
immunotherapy- treated patients with concomitant HBV 
or HCV infections (among which HCC was the most 
common tumor type) found no evidence for viral reacti-
vation and similar incidences of grade ≥3 irAEs, as well as 
ORRs compared with those observed in registration trials 
of approved anti- PD-1 therapy.130 However, the immune 
landscape of HBV- associated HCC is generally thought 
to be profoundly suppressed and exhausted, which could 
potentially alter the efficacy of ICI therapy. A pooled 
analysis of anti- PD- (L)1 therapy trials for HCC found that 
although HBV- positive patients achieved ORRs compa-
rable to those of HBV- negative patients (OR 0.68; 95% CI 
0.37 to 1.25; p=0.21), the DCRs were significantly lower 
for HBV- positive patients compared with HBV- negative 
patients (OR 0.49; 95% CI 0.27 to 0.89; p=0.02).131
A recent meta- analysis by Pfister et al132 found differen-
tial survival outcomes depending on HCC etiology in 1,656 
patients in randomized trials of ICIs as monotherapy or 
in combination with bevacizumab. In the analysis, check-
point blockade was not associated with improved survival 
in patients with non- viral HCC, in marked contrast to the 
overall cohort and patients with viral etiology. In addi-
tion, survival was also diminished in two smaller cohorts 
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of patients with HCC and documented NAFLD. Although 
provocative and interesting, future prospective confirma-
tory studies are needed to understand if and how etiology 
affects the liver immune microenvironment. Of note, a 
separate study that did not include patients treated in 
IMbrave150 found no differences in ORRs nor features 
of the tumor microenvironment (TME) that are known 
to modulate responses to ICIs between patients with viral 
and non- viral HCC.133
Relatively few trials have included patients with Child- 
Pugh B cirrhosis, a population for which few treatment 
options are available. In a retrospective case series of 18 
patients with Child- Pugh B cirrhosis and advanced HCC 
who were treated with nivolumab, 94% (17 of 18) expe-
rienced a grade ≥3 AE, with treatment- related grade ≥3 
AEs reported in 28% (5 of 18). IrAEs were reported in 
50% of patients (9 of 18), and 28% (5 of 18) required 
steroids. Treatment- related AEs led to discontinuation 
of therapy in four patients (22%).59 In the Child- Pugh 
B cohort of CheckMate 040, 49 patients with Child- Pugh 
B7 to B8 advanced HCC who were sorafenib- naïve (n=25) 
or sorafenib- experienced (n=24) received nivolumab 
monotherapy. Investigator- assessed ORR was 12% (95% 
CI 5% to 25%) and the DCR was 55% (95% CI 40% to 
69%). Safety was similar to that seen with nivolumab in 
patients with Child- Pugh A disease. At a median follow- up 
of 16.3 months, median OS was 7.6 months for the entire 
cohort—median OS in sorafenib- naïve and sorafenib- 
treated patients were 9.8 and 7.4 months, respectively.61 
Importantly, there is no evidence to date indicating that 
immunotherapy causes further damage to impaired livers.
Patients with tumor invasion of the main trunk of the 
portal vein, invasion of the portal vein branch contra-
lateral to the primarily involved lobe (Vp4), bile duct 
invasion, and/or tumor occupying ≥50% of the liver are 
considered high risk. Data from IMbrave150 indicates 
that atezolizumab with bevacizumab is safe and effective 
in patients with high- risk features. Although more grade 5 
upper gastrointestinal hemorrhage events were reported 
in high- risk patients receiving atezolizumab with bevaci-
zumab, none of these grade 5 events were considered by 
investigators to be related to treatment.134 However, vari-
ceal bleeding is a potential toxicity of anti- VEGF agents. 
Therefore, for patients treated with atezolizumab in 
combination with bevacizumab, esophagogastroduode-
noscopy to evaluate for varices within 6 months of initi-
ating therapy is recommended.135
Finally, patients who have received liver transplants are 
typically excluded from clinical trials due to concerns 
about graft rejection, and high rates of rejection and 
mortality have been reported in the limited cases 
published thus far.87
Biomarkers for ICI efficacy and safety in HCC
ICIs provide benefit for only a subset of patients. The 
ability to identify intrinsic resistance to ICIs would allow 
patients to attempt other therapies, which could, most 
importantly, lead to better outcomes, while also saving 
healthcare resources. Unfortunately, validated blood or 
tissue biomarkers for ICI resistance are currently lacking 
in the clinical setting. Early studies have also returned 
conflicting results. High serum AFP levels are associ-
ated with increased sensitivity to the anti- VEGF receptor 
(VEGFR) monoclonal antibody ramucirumab.136 Post 
hoc subgroup analysis of randomized trials have shown 
that the HR for OS was slightly lower among patients with 
high AFP in KEYNOTE-240 (pembrolizumab vs placebo)65 
and CheckMate 459 (nivolumab vs sorafenib),137 while 
the contrary was observed in IMbrave150 (atezolizumab 
with bevacizumab vs placebo).16 69 Furthermore, objec-
tive remissions occur irrespective of AFP levels after 
nivolumab or pembrolizumab monotherapies, or the 
combination of ipilimumab and nivolumab.
A number of features of the tumor microenvironment 
have been associated with HCC prognosis, including 
overall lymphocyte infiltration, density of Tregs, and 
tumor- associated macrophages (TAMs), especially if 
M2- polarized. In melanoma, the presence of conven-
tional type 1 dendritic cells seems critical to promote a 
T and NK cell infiltrate and for the action of ICIs.138 In 
HCC animal models, β-catenin- mutations in HCC (which 
are present in around 25% of human HCCs) result in 
a paucity of intratumoral conventional type 1 dendritic 
cells,139 and it has been proposed that β-catenin defects 
may be used to identify patients with disease that will 
fail to respond to PD-1 blockade.140 This feature awaits 
investigation in clinical trials. Soluble factors also modu-
late the immune response against HCC. For example, 
transforming growth factor beta (TGF-β) downregulates 
antitumor responses through a variety of different mecha-
nisms, and high levels of the cytokine shape the response 
to pembrolizumab.141
Pretreatment tumor infiltration by T cells and their 
activity status are key to determine response to ICIs in 
various cancers. In advanced HCC, CD4+ and CD8+ T cell 
infiltration showed weak correlations with survival after 
second- line treatment with PD-1 inhibitors in Check-
Mate 040.142 In the trial, deep antitumor responses were 
observed regardless of PD- L1 expression after nivolumab 
treatment, although the response rate was higher among 
patients with at least 1% of tumor cells expressing 
PD- L1.142
On the other hand, PD- L1 expression in tumor or 
stromal immune cells was higher among responders to 
pembrolizumab, but remissions also occurred in the 
absence of expression in both cell types.65 In CheckMate 
459, median OS after nivolumab and sorafenib was 16.1 
months versus 8.6 months among patients that had tumor 
PD- L1 expression ≥1% (HR 0.80), and 16.7 months versus 
15.2 months among those that had tumor PD- L1 expres-
sion <1% (HR 0.84).137 Interestingly, macrophage infil-
tration, including M2- polarized TAMs, was not associated 
with clinical outcomes after nivolumab treatment. A meta- 
analysis including 894 patients across nine trials of ICIs 
in advanced HCC found a positive association between 
PD- L1 expression and response to therapy—especially for 
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single- agent anti- PD-1. Strikingly, in the analysis, PD- L1 
expression status had minimal association with response 
to therapy for patients being treated with anti- CTLA-4- 
containing combinations.143 Analytical heterogeneity 
in PD- L1 expression is substantial, however, and may 
contribute to the performance of this test as a predictive 
biomarker.144
Several inflammatory gene signatures are correlated 
with higher response rate and improved OS after 
nivolumab treatment.142 Interestingly, the most complex 
transcriptomic classifications of inflammatory HCC 
including a large number of genes145 were not identified 
as predictive of response in this analysis, suggesting that 
short gene signatures may be more relevant for clinical 
development. Regarding ICI combinations, objective 
remissions occurred with ipilimumab plus nivolumab 
irrespective of PD- L1 expression in tumor cells.146 An 
early burst of Ki67+CD8+ cells in the peripheral blood 
was also seen in one of the randomized expansion 
cohorts for Study 22, which evaluated combinations of 
durvalumab and tremilimumab at different dosing regi-
mens,74 hinting that cytotoxic T cell proliferation after 
therapy may predict response. Altogether, though, it 
seems unlikely that a single biomarker could be used to 
inform clinical decisions in a timely fashion. However, 
it is probable that composed and integrative multifacto-
rial indexes might help identify patient subsets who are 
likely to benefit, further underscoring the importance of 
obtaining pretreatment tumor biopsies for future transla-
tional studies.
Pembrolizumab is FDA- approved for two tissue- 
agnostic indications based on tumor- intrinsic character-
istics. Approval for pembrolizumab for the treatment of 
microsatellite- high (MSI- H) or mismatch repair deficient 
(dMMR) tumors was based on a pooled ORR of 39.6% 
(95% CI 31.7% to 47.9%), with a 7% CR rate among 149 
patients with 15 different tumor types in five single- arm 
multi- cohort multicenter trials: KEYNOTE-016,147 
KEYNOTE-164,148 KEYNOTE-012149 KEYNOTE-028,150 
and KEYNOTE-158.151 Approval for pembrolizumab 
for non- MSI- H/dMMR tumors with high mutation 
burden (TMB- H)—defined as ≥10 mutations per mega-
base (mut/Mb) as assayed by the FoundationOne CDx 
companion diagnostic—was based on KEYNOTE-158.152 
No patients with HCC were included in the cohorts upon 
which the tissue- agnostic indications for pembrolizumab 
were approved, however.
TMB correlates with the number of neoantigens and 
response to ICIs in tumors with >20 somatic mut/Mb, 
such as melanoma.153 154 However, HCC is infrequently 
MSI- H/dMMR or TMB- H. One study that performed 
comprehensive genomic profiling of 755 patients with 
advanced HCC found a median TMB of 4 mut/Mb and 
that only six tumors (0.8%) were TMB- H. Furthermore, 
out of 542 cases assessed, only one (0.2%) was MSI- H.155 
Another analysis found a rate for MSI- H as low as 6%.156
Markers of systemic inflammation like neutrophil to 
lymphocyte ratio (NLR) and platelet to lymphocyte ratio 
(PLR) have shown a strong prognostic impact in HCC 
across tumor stages. Lower NLR has been associated 
with better outcomes after sorafenib,157 158 and similar 
trends are emerging from trials of ICIs. In CheckMate 
040, patients progressing on nivolumab had a higher 
NLR and PLR than patients who had disease control as 
the best overall response.142 Consistent with this observa-
tion, a retrospective analysis of 103 patients who received 
nivolumab found that patients with Child- Pugh A disease 
who achieved PR or CR had significantly lower post- 
treatment NLR and PLR (p<0.001 for both) compared 
with patients who had stable or progressive disease.159
The composition of the gut microbiota, which has 
been linked to the promotion of HCC development and 
progression through secreted metabolites,160 161 may also 
predict response to treatment, although current anal-
yses in the liver cancer setting are small and preliminary. 
Gut microbial diversity has been linked to ICI efficacy in 
epithelial tumors,162 and retrospective analysis has shown 
that antibiotic use is associated with worse outcomes with 
immunotherapy in lung and renal cancer,163 a finding that 
has also been replicated in a prospective trial including 
several additional tumor types.164 One pilot study of eight 
patients with HCC treated with anti- PD-1 therapy after 
progression on sorafenib found that patients with respon-
sive disease displayed higher taxa richness and more 
gene counts in their microbiota compared with non- 
responders, with enrichment for 20 distinct species of 
bacteria, including Akkermansia muciniphila and the Rumi-
nococcaceae family.165 The potential for the gut microbiota 
to shape responses to immunotherapy is an ongoing area 
of research, but, at present, the state of the data is not 
sufficient to alter management in this regard and clinical 
judgment outweighs other considerations.
An additional ongoing area of research is the identifi-
cation of biomarkers for the prediction of which patients 
will experience irAEs with ICI therapy. Several studies 
have reported a link between various clinical and blood- 
based or serological factors and the onset of immune- 
related toxicity, although none have been prospectively 
validated for HCC. Patients with sarcopenia166 167 and of 
female sex168 169 have both been shown to have higher 
incidences of irAEs. Additionally, the composition of 
the gut microbiota may play a role in predicting which 
patients will develop ICI- associated colitis.170 Additional 
factors under active investigation for prediction of toxicity 
include elevated cytokine levels at baseline, such as inter-
leukin (IL)-6169 and IL-17,171 as well as the presence of 
autoantibodies.172 173 Currently there are no clinically vali-
dated biomarkers to predict the risk of irAEs.
Recognition and management of irAEs
The same mechanisms by which immunotherapy drugs 
exert their therapeutic effects also underlie their unique 
toxicities—suppression of the inhibitory mechanisms that 
protect tissues from uncontrolled immune responses. 
Unlike AEs with chemotherapy or other treatment modal-
ities, irAEs may be delayed in onset and have prolonged 
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duration, sometimes months or years after initial expo-
sure to therapy. The overall incidence and severity of 
irAEs reported in phase III trials of anti- PD- (L)1 agents 
varies depending on disease state and comorbidities. 
Most irAEs are of mild- to- moderate severity, but life- 
threatening events have been reported. A meta- analysis 
of fatal ICI- associated toxicities encompassing more than 
16,000,000 adverse drug reactions from the medical 
records from the VigiBase- VigiLyze database found a 
total of 613 deaths related to ICIs. The fatalities related to 
anti- CTLA-4 therapy were most often from colitis (n=135, 
70%), while fatalities associated with anti- PD- (L)1 were 
most often from pneumonitis (n=333, 35%), hepatitis 
(n=115, 22%), and neurotoxic effects (n=50, 15%).174 
A systematic review including 48 clinical trials involving 
7,936 patients treated with nivolumab monotherapy or 
combination nivolumab and ipilimumab found that the 
double regimen was associated with more all- grade and 
grade ≥3 irAEs categorized by system, organ, or class 
(p<0.05). Additionally, the ORR of nivolumab combined 
with ipilimumab was positively correlated with the inci-
dence rate of skin (r=0.54; p=0.04) and gastrointestinal 
irAEs (r=0.60; p=0.02), but not endocrine, hepatic, 
pulmonary, or renal irAEs.175 Similarly a recent observa-
tional study including 331 patients with HCC receiving 
anti- PD- (L)1 monotherapy or combinations found that 
the emergence of treatment- related AEs of grade ≥2 while 
on ICI therapy predicted for improved OS (median 19.7 
vs 11.0 months; HR 0.32; 95% CI 0.16 to 0.65; p=0.001) 
and increased ORR (30% vs 16%; χ2 5.9; p=0.01).176
Typically, the management of irAEs includes inter-
ruption of ICIs, corticosteroids, and occasionally the 
administration of immunomodulatory agents including 
tumor necrosis factor (TNF) inhibitors. Detailed recom-
mendations on the recognition and management of 
ICI- associated AEs have been published elsewhere177 
and the general principles contained therein may guide 
treatment decisions for irAEs, which are not specific to 
patients with HCC.
IrAEs specific to the treatment of HCC
Outside of immune- mediated hepatotoxicity, the 
commonly reported AEs in published trials leading 
to ICI approvals for HCC have been generally compa-
rable to those seen in other disease settings. Pembroli-
zumab monotherapy showed a tolerable safety profile 
in KEYNOTE-224, with the most common irAEs of any 
grade being hypothyroidism (n=8, 8%) and adrenal insuf-
ficiency (n=3, 3%).14 In the cohort of patients receiving 
nivolumab monotherapy in CheckMate 040, the most 
common AEs were pruritus (n=9, 11%) and rash (n=11, 
23%).13 The addition of ipilimumab to nivolumab, as eval-
uated in cohort 4 of CheckMate 040, was associated with 
a wider variety of toxicities with the most common AEs of 
any grade being rash (n=14, 29%), pruritus (n=22, 45%), 
diarrhea (n=12, 24%), decreased appetite (n=6, 12%), 
fatigue (n=9, 18%), adrenal insufficiency (n=7, 14%), and 
hypothyroidism (n=10, 20%).178 For the combination of 
atezolizumab with bevacizumab in IMbrave150, the most 
common adverse reactions were hypertension (n=98, 
29.8%), fatigue (n=67, 20.4%), and proteinuria (n=66, 
20.1%), and no serious AEs with a difference in incidence 
of >2% were noted between the atezolizumab with bevaci-
zumab and sorafenib treatment groups.16
Drug-induced hepatotoxicity
HCC usually develops in a background of chronic liver 
disease, which itself may give rise to systemic manifesta-
tions. Cirrhosis is characterized by diffuse fibrosis of the 
liver, altered hepatic blood flow and portal hypertension, 
and progressive failure of liver functions. In parallel, other 
organs frequently develop secondary dysfunction. Many 
extrahepatic disorders associated with cirrhosis cause 
symptoms that may mimic irAEs and therefore lead to 
overdiagnosis or underdiagnosis of toxicities with immu-
notherapy. Late recognition of irAEs may delay treatment 
and worsen the prognosis. Overdiagnosis may result in 
inappropriate interruption of ICIs, complications caused 
by immunosuppressive therapy, unnecessary diagnostic 
procedures, and increased cost. Such disorders can also 
synergize in causing deteriorating organ function when 
irAEs occur. The most important cirrhosis- related disor-
ders that may compromise the management of irAEs are 
summarized in table 5.
Patients with HCC and underlying liver disease are at 
high risk for decompensation with additional insult to 
the organ. Some studies have found that underlying liver 
disease as opposed to cancer progression is the ultimate 
cause of death in almost half of patients with HCC.108 
Elevated liver enzymes without clinical impairment in 
hepatic function were commonly reported in all of the 
trials that led to approvals of ICIs for HCC.13–15 Grade 3 
or 4 elevations in liver enzymes were reported in 16% of 
patients in the dose‐escalation arm of CheckMate 040 and 
in 12% of the patients in KEYNOTE‐224.14 In KEYNOTE-
240, immune- mediated hepatitis events were seen in 10 
patients (3.6%) in the pembrolizumab group, approxi-
mately 90% of which resolved.65
No prospective trials have defined the best treatment 
approach for drug- induced hepatotoxicity in patients 
with HCC receiving immunotherapy. The package inserts 
for pembrolizumab, nivolumab, and atezolizumab all 
recommend monitoring for changes in liver function and 
administering corticosteroids for hepatitis followed by a 
taper. ICIs should also be withheld or discontinued if liver 
enzymes or bilirubin become elevated, with the thresh-
olds varying depending on baseline values and the drug 
regimen being given.179 Exclusion of other causes of acute 
liver damage—including toxicities from concomitant 
medications, use of herbal supplements, viral hepatitis, 
and particularly tumor progression—is key to adequate 
management.
Response evaluation
Measurement of response rate in HCC has been contro-
versial. The WHO (WHO) criteria180 and the RECIST 
 on O














15Greten TF, et al. J Immunother Cancer 2021;9:e002794. doi:10.1136/jitc-2021-002794
Open access
guidelines181 define standard measurement methods for 
converting radiology image observations into quantita-
tive and statistically tractable frameworks for measuring 
changes in tumor size associated with therapy. However, 
assessments based solely on tumor size are misleading 
when applied to molecular targeted therapies and immu-
notherapies. For HCC in particular, poor correlation has 
been shown between the clinical benefits provided by 
sorafenib or locoregional interventional therapies and 
RECIST- based responses.182 Subsequently, the concept 
of ‘viable tumor’ was endorsed by the guidelines for the 
design of HCC clinical trials developed by AASLD183 
and eventually incorporated into a formal proposal to 
amend standard RECIST criteria to address the unique 
complexity of HCC response assessment. The amended 
criteria were named mRECIST for HCC.184 In published 
trials of immunotherapy for HCC, RECIST v1.1 was used. 
In the immunotherapy setting, no significant differences 
exist between RECIST and mRECIST.
Several clinical investigations have shown that objec-
tive response measured by mRECIST predicts survival in 
patients treated by locoregional therapies. A meta- analysis 
including seven trials and 1,357 patients reported an OS 
HR (responders vs non- responders) of 0.39 (95% CI 0.26 
to 0.61; p<0.0001).185 Another study found that EASL 
and mRECIST both outperformed the WHO criteria and 
Table 5 Cirrhosis- related disorders that should be considered in the diagnostic workup of irAEs in patients with HCC 
(Adapted from Sangro et al, J Hepatol 2020)179
Organ irAE Chronic liver disease
Skin  ► Pruritus
 ► Rash
 ► Erythema multiforme, 
psoriasis, urticaria and 
rosácea
 ► Severe cutaneous adverse 
reactions
 ► Pruritus
 ► Skin disorders, including lichen planus, polyarteritis nodosa, 
cryoglobulinemic vasculitis, and porphyria cutanea tarda (HCV- and 
HBV- related)
GI tract  ► Diarrhea
 ► Colitis
 ► Small intestine bacterial overgrowth
 ► Chronic pancreatitis
Liver  ► Hepatitis  ► Flares or viral infection
Lung  ► Pneumonitis  ► Hepatopulmonary syndrome
 ► Porto- pulmonary hypertension
Thyroid  ► Hypothyroidism
 ► Hyperthyroidism
 ► Graves’ disease
 ► Reduced peripheral conversion of T4 to T3




 ► Adrenal insufficiency
 ► Hypophysitis
 ► Hypogonadism
 ► Hypothalamic- pituitary dysfunction
 ► Relative adrenal insufficiency
Kidney  ► Nephritis  ► Hepatorenal syndrome
 ► Mixed cryoglobulinemia (HCV- related)
 ► HBV- related nephropathy
 ► IgA nephropathy
Nervous system  ► Encephalitis
 ► Aseptic meningitis
 ► Peripheral neuropathy
 ► Myasthenia gravis
 ► Guillain- Barre syndrome
 ► Autonomic neuropathy
 ► Transverse myelitis
 ► Porto- systemic encephalopathy (typical and atypical)
 ► Viral- related peripheral neuropathy
 ► Wernicke’s encephalopathy
 ► Autonomic neuropathy (HCV- related)
Blood and bone 
marrow
 ► Cytopenias
 ► Hemolytic anemia
 ► Red cell aplasia
 ► Bone marrow failure
 ► Hemophilia A
 ► Hemophagocytic 
lymphohistiocytosis
 ► Macrophage activation 
syndrome
 ► Hypersplenism and bone marrow depression
 ► Anemia due to folate or iron deficiency
 ► Hemolytic anemia
 ► Viral- related thrombotic thrombocytopenic purpura and aplastic anemia
 ► Immune thrombocytopenia (HCV- related)
 ► Lymphopenia related to HCC therapies
GI, gastrointestinal; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; irAE, immune- related adverse event.
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RECIST for patients undergoing DEB- TACE.186 Recently, 
data from randomized trials confirmed that objective 
response by mRECIST predicts survival in patients with 
advanced- stage HCC receiving systemic therapies with 
TKIs, and suggested that objective response by mRECIST 
can be considered as a candidate surrogate end point of 
OS, although further research is needed to support this 
finding.187 188
Although late response after apparent disease progres-
sion on imaging has been reported in the context of 
immunotherapy for HCC,189 the overall incidence of 
pseudoprogression with ICI treatment is rare. Estimated 
rates of psuedoprogression across published studies range 
from 2%–10%.190 191 Also rare, though possible, is a rapid 
acceleration in tumor growth after anti- PD- (L)1 therapy, 
a phenomenon called hyperprogression.191 192 Although 
published evidence is limited, hyperprogression has been 
reported in small case series of patients with HCC treated 
with ICIs,193 and retrospective analyses.194 Importantly, 
the evidence to date has only reported hyperprogression 
in the setting of anti- PD- (L)1 monotherapy—it is unclear 
whether the addition of VEGF- directed antibodies to ICI 
therapy affects the likelihood of hyperprogressive disease 
after treatment.
Panel recommendations
 ► For patients with advanced- stage HCC and for 
patients with earlier- stage disease where liver- directed 
therapies are not considered appropriate or who 
have progressed after liver- directed therapy, the data 
at present supports first- line and subsequent- line ICI 
therapy use (LE: 2). Further studies are needed to 
confirm the efficacy of immunotherapy in the cura-
tive setting (neoadjuvant/adjuvant/perioperative) or 
in conjunction with intra- arterial therapies.
 ► In patients with HCC with cirrhosis, the data supports 
the use of immunotherapy in patients with under-
lying synthetic liver function consistent with well- 
compensated cirrhosis, specifically Child- Pugh A (LE: 
2). The panel recognizes, however, that some care-
fully selected patients with Child- Pugh B may derive 
benefit (LE: 3).
 ► Patients who have contraindications for the use of 
TKIs or anti- VEGF therapies (eg, cardiovascular 
comorbidities) may be suitable for anti- PD-1 mono-
therapy (LE: 1).
 ► The panel recommends against the use of immuno-
therapy in the post- transplant setting (LE: 4) due to 
the high risk of graft failure, given known mecha-
nisms of ICIs.
 ► Additional studies are needed to assess the potential 
risks and benefits of immunotherapy in the pretrans-
plant setting.
 ► The panel agrees that patients can be considered for 
immunotherapy treatment irrespective of hepatitis 
viral etiology (LE: 3), though it is strongly recom-
mended that patients with HBV be on concomitant 
antiviral medication and adherent.
 ► While patients living with HIV have not been included 
in clinical trials to date, the panel believes that this 
is not an absolute contraindication to treatment 
with immunotherapy as long as the appropriate HIV 
therapy is instituted as per expert guidance (LE: 2), 
while further dedicated studies to assess such thera-
pies in patients living with HIV remain critical.
 ► Historical disparities in access to clinical trial partic-
ipation for underrepresented groups should be 
considered, with efforts made to support diversity, 
equity, and inclusion.
 ► The panel recommends against the use of routine 
testing of biomarkers for predicting immunotherapy 
efficacy, which, at this point, remains exploratory.
 ► The panel recommends against the use of routine 
testing of biomarkers for predicting irAEs, which, at 
this point, remains exploratory.
 ► Response assessment can be performed according to 
mRECIST criteria in patients receiving locoregional 
interventional therapies (LE: 3).
 ► Limited data are available concerning the value of 
mRECIST and immune- related RECIST (irRECIST) 
criteria in the setting of HCC response assessment, 
especially in the context of ICI therapy. Further 
studies are needed to compare outcomes between 
patients with response to treatment by mRECIST 
versus irRECIST.
 ► Pseudoprogression, while a real phenomenon, occurs 
rarely (LE: 4). A comprehensive assessment is encour-
aged. In published trials, treatment beyond progres-
sion has been allowed.
 ► Hyperprogression may occur (LE: 4). It is uncommon, 
cannot be anticipated, and remains poorly understood.
 ► Caution should be exercised in translating response 
assessment models developed for clinical trials into 
clinical practice.
 ► For management of irAEs in patients with HCC, refer 
to general principles in published guidelines.
PATIENT SUPPORT AND QOL
Immunotherapies and targeted therapies have extended 
survival for patients with HCC, but these new agents are 
not curative in most cases, and their unique toxicities can 
affect QOL. The importance of QOL as an independent 
prognostic factor for response to treatment or predicting 
disease progression is becoming more appreciated—
several studies have demonstrated associations between 
baseline patient- reported QOL and survival in HCC.195–197 
Therefore, immunotherapy treatment plans should take 
patient QOL at baseline and on therapy into account. 
Additionally, it is important for clinicians to provide 
patients with necessary and sufficient information to 
help them navigate treatment without undue emotional 
or financial distress. Referral to support groups is also 
highly encouraged, including the American Liver Foun-
dation, Blue Faery: The Adrienne Wilson Liver Cancer 
Association, Cancer Support Community, the Fatty Liver 
Foundation, and the Global Liver Institute. In addition, 
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information provided by the National Cancer Institute 
and SITC may be helpful for patients.
Patient and caregiver education
Prior to diagnosis, the majority of patients and their care-
givers will likely be unfamiliar with HCC, and they may 
harbor misconceptions about the etiology of the disease, 
potentially leading to stigma and shame over and above 
the emotional distress associated with a cancer diag-
nosis.198 Among different types of cancer, HCC has been 
found to rank third highest in terms of levels of emotional 
distress experienced by patients.199 Rehabilitation, palli-
ative care, and psycho- oncology have been insufficiently 
studied in liver cancer.
Perceived stigma surrounding liver disease may cause 
patients to delay care or avoid seeking social support, 
which negatively impacts QOL.200 The majority of HCC 
cases worldwide are secondary to HBV or HCV infection,4 
with NASH increasingly becoming the primary cause in 
the US and Europe.5 However, a survey of HCC care-
givers in the US found that 72% were under the mistaken 
impression that heavy alcohol use was the most common 
risk factor for liver cancer.201 Stigma surrounding HBV 
may be more pronounced in certain populations, such as 
people of Asian descent,202 203 so it is important for health-
care providers to be sensitive and culturally informed in 
their communications with patients.
HCC is a disease within a disease, and patients as well as 
their caregivers need to understand that their treatment 
journey will involve both the cancer itself as well as under-
lying liver damage. Patients with HCC often receive care 
from a multidisciplinary team that may include oncolo-
gists, hepatologists, surgeons, gastroenterologists, endo-
crinologists, and other specialists. In addition to the care 
team responsible for administering therapy targeting the 
tumor and the liver, patients will need ‘whole- person’ 
support for psychosocial and spiritual concerns, especially 
during end- of- life care.204 205 Depending on the stage of 
their disease (for more details on staging systems for HCC, 
see the Diagnostics and staging for patients with HCC 
section), a patient may be receiving information from a 
large number of different providers, especially in cases 
of intermediate- stage HCC.205 Additionally, practitioners 
from other specialties may have limited knowledge about 
the unique mechanisms of action of immunotherapies, 
and the accompanying potential for toxicities, making 
ongoing communication between a patient and their 
treating oncologist paramount.
Currently, immunotherapy is only approved for patients 
with advanced disease. Patients may be unfamiliar with 
the stages of liver cancer and the difference between 
treatments with curative intent and palliative therapy. 
Further complicating matters, patients may have precon-
ceived notions shaped by media portrayals of high- profile 
immunotherapy success stories, while being less knowl-
edgeable about the realistic efficacy and potential toxici-
ties with treatment.206 Early referral to palliative care has 
been shown to improve QOL in patients with non- small 
cell lung cancer,207 yet palliative care is underutilized in 
patients with end- stage liver disease.208 209 Patients with 
cirrhosis who are ineligible for transplant are also under-
served with appropriate palliative care.210 It is important 
for patients to understand that immunotherapy for HCC, 
even if it may extend OS, is a palliative treatment used in 
advanced stages of the disease and not curative in intent, 
so that they may be referred to advanced care planning 
early on in their treatment.
Considerations for administration, dosing and monitoring
The tolerability of immunotherapy is, for the most part, 
better than conventional cancer treatments, although 
future combination strategies (eg, ICIs with TKIs) may 
be associated with less favorable toxicity profiles.211 The 
administration, dosing, and monitoring considerations 
for immunotherapy may be distinct from what a patient 
or caregiver is expecting based on experience with prior 
therapies or conversations with other healthcare providers 
who do not specialize in immunotherapy. Therefore, it is 
important to discuss the potential for irAEs and the signs 
and symptoms of expected toxicities with patients and 
caregivers. Additionally, patients must understand how 
liver comorbidities may affect the efficacy of immuno-
therapy for HCC (see the Patient selection and manage-
ment section for considerations for healthcare providers). 
It is important for patients and caregivers to have clear 
and detailed instructions for when to contact their health-
care providers due to symptoms of irAEs, and examples of 
call parameters are provided in box 1.
Box 1 Patient and caregiver education for call 
parameters for irAEs
You should contact your healthcare providers for any of the following 
symptoms (or call 911 or seek emergency services as indicated)*:
 ► Abdominal pain
 ► Change in stool (blood or mucus in stool, change in color, light or 
clay colored)
 ► Increase in bowel movements, >3 movements above a patient’s 
baseline
 ► Diarrhea, >3 watery stools
 ► Nausea or vomiting
 ► Jaundice (yellowish skin color)
 ► Difficulty breathing, shortness of breath, or chest tightness
 ► New non- productive dry cough
 ► Mental status changes
 ► New visual disturbances
 ► Headache
 ► New or worsening fatigue
 ► Fever with temperature >100.4oF (38°C)
 ► New weakness, muscle or joint pains
 ► Unintentional weight loss >3 lbs (1.5 kg)
 ► Significant weight gain with obvious abdominal swelling
 ► Rash which may or may not be accompanied by tenderness or 
itching
*Note to providers: Call parameters for patients highlight the following 
conditions: colitis, pneumonitis, endocrinopathies, dermatologic toxicities. It 
should be noted that many conditions have overlapping symptoms.
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The ICIs that are currently approved for HCC are typi-
cally given as IV infusions, whereas TKIs such as sorafenib 
are oral medications. Because immunotherapy is usually 
administered at an infusion center, access to care may be 
a challenge for some patients, especially those in rural 
areas.212 213 However, a potential benefit of the require-
ment for inperson infusions is the opportunity for contact 
with a treating physician if AEs do occur. Additionally, 
although patients receiving palliative chemotherapy have 
been found to prefer oral administration over IV, the 
majority are not willing to accept a decreased response 
rate or shorter DOR,214 which is likely also true when 
deciding between IV immunotherapy versus other oral 
medications.
Multiple liver- specific assessment instruments have 
been developed to monitor QOL in patients with HCC, 
including the European Organization for Research 
and Treatment of Cancer Quality of Life Questionnaire 
Core-18 (EORTC QLQ- HCC18),215 the Functional Assess-
ment of Cancer Therapy- Hepatobiliary (FACT- Hep),216 
the FACT Hepatobiliary Symptom Index (FHSI),217 and 
the QOL- liver cancer (QOL- LC).218 However, multiple 
systematic reviews have found that the most used assess-
ment tool is the EORTC Quality of Life Questionnaire 
Core-30 (EORTC QLQ- C30).219 220
Special considerations for patients with HCC
Patients with HCC have been found to have lower health- 
related QOL (HRQOL) than the general population, 
especially for measures of physical, psychological, and 
functional well- being, as well as hepatobiliary symp-
toms.219 Both physical and psychological factors may influ-
ence a patient’s QOL, and a person’s self- perception and 
coping mechanisms may modulate their status. In patient 
interviews, HCC has been found to be perceived as a long- 
term and chronic disease that cannot be cured but might 
be controlled, and coping strategies can include focusing 
as much as possible on managing HCC and its symptoms, 
emotional responses, and leading a normal life.221 Those 
mental constructs can affect feelings about physical 
symptoms, and it has been demonstrated that patients 
with negative illness perceptions who use more emotion- 
oriented coping had worse HRQOL.222 However, rigorous 
studies on interventions targeting disease perception or 
coping mechanisms are currently lacking.
Pain, particularly upper quadrant abdominal pain, 
is common in patients with HCC.223 Pain management 
may be difficult because approximately 80% of patients 
with HCC have cirrhosis,224 and liver damage can alter 
drug pharmacokinetics. Perhaps due to confusion about 
efficacy and safety for opioid and non- opioid analgesics, 
patients with HCC are undertreated for pain.225 However, 
some generally safe options for pain management for 
patients with impaired liver function exist, including 
opioids, non- steroidal anti- inflammatory drugs (NSAIDs) 
in some cases, topical lidocaine patches (which have low 
levels of systemic absorption) for localized analgesia, 
tricyclic antidepressants, and anticonvulsants such as 
gabapentin (which is not metabolized by the liver).226
Financial toxicity is a major concern for patients with 
cancer,227 and immunotherapies are among the most 
expensive agents on the pharmaceutical market.228 229 
Patients with cancer shoulder the burden of an increasing 
number of out- of- pocket costs for their treatment, even 
if they have insurance coverage.230 Treatment may cause 
both material and psychological financial hardship, and 
the risk factors for each vary. Patients of younger age, 
female sex, non- white race, and who change employment 
because of cancer are more likely to experience mate-
rial financial hardship, whereas psychological hardship 
is more likely among those who are uninsured or have 
lower family income.231 The degree to which cancer 
causes financial burden has been shown to be the single 
most important predictor for poor QOL,232 and health-
care costs for HCC are substantial. In both North America 
and Asia, costs are highest for patients with HCC in the 
terminal phase of care.233 Although a comprehensive 
analysis of the healthcare costs associated with immuno-
therapy in the HCC setting has not yet been performed, 
oncologists should communicate with patients about how 
treatment may affect their financial well- being, as health 
insurance may not cover the costs of immunotherapy 
drugs.
Importantly, however, immunotherapy has generally 
been associated with favorable QOL outcomes compared 
with previous standards of care. In the landmark trials 
leading to FDA approval of checkpoint inhibitors for 
HCC, no adverse effects on QOL were observed when 
outcomes were reported for the patients receiving immu-
notherapy. Nivolumab was associated with stable patient- 
reported outcomes, including indicators of health status 
and QOL regardless of prior sorafenib in CheckMate 
040.13 It is noteworthy to mention that even in a subcohort 
of patients from the CheckMate 040 trial with impaired 
liver function (Child- Pugh B), the AE profile was compa-
rable to what was seen in patients with Child- Pugh A 
disease.59 Additionally, IMbrave150 provided a large and 
rich data set on patient- reported QOL outcomes, which 
complemented the efficacy data, with a reporting rate of 
greater than 90%. The study found that fewer patients 
treated with the combination of atezolizumab with beva-
cizumab experienced QOL deterioration compared with 
those receiving sorafenib. Furthermore, for the patients 
who did experience QOL deterioration on immuno-
therapy, the onset was later.234 Pembrolizumab also was 
shown to preserve HRQOL in a prespecified exploratory 
analysis of patients enrolled in KEYNOTE-240. Among 
the 271 and 127 patients randomly assigned to pembroli-
zumab and placebo, respectively, who completed the 
EORTC QLQ- C30 and the HCC supplement EORTC 
QLQ- HCC18, changes in both scores were similar across 
arms and global health status/QOL scores were stable.235 
It will be important to prospectively study QOL outcomes 
in future immunotherapy trials, especially as new combi-
nation regimens advance through clinical development.
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Panel recommendations
 ► Patient and caregiver education for HCC should 
include an overview of the liver’s function in the body, 
an explanation of underlying liver diseases such as 
HBV, HCV, and NASH, and a discussion of how immu-
notherapy works to treat their cancer.
 ► Patients must know which provider is coordinating 
their treatment, and they need to have clear instruc-
tions to promptly report any signs or symptoms of 
potential immune- related toxicities.
 ► Patients need counseling on the goals of treatment in 
advanced HCC, which is not curative in most patients, 
despite significant advances. Management of HCC 
should include focus on supportive care for uncon-
trolled symptoms and inclusion of palliative care 
specialists.
 ► Patients should receive education on the expected 
toxicities associated with immunotherapies, including 
hepatitis, colitis, pneumonitis, and immune- related 
endocrinopathies. Detailed call parameters should be 
provided to promptly report signs and symptoms of 
irAEs.
 ► Assessment of patients’ physical function and symp-
toms should be performed before, during, and after 
therapy.
 ► Patients should be referred to a treatment team 
including a social worker and a financial manager to 
assist in navigating healthcare costs and identifying 
support systems.
 ► Conversations should be initiated with patients about 
how the costs of immunotherapy treatment will be 
covered, including contributions from private insur-
ance, Medicare and Medicaid, clinical trials, patient 
assistance programs, or compassionate use as needed.
 ► Patients should be provided information about local 
advocacy and support groups specific to primary liver 
cancer.
CONCLUSION
Immunotherapy represents a major breakthrough for the 
treatment of advanced HCC, offering some of the first 
demonstrated improvements for patient outcomes over 
standard- of- care systemic therapies since the late 2000s. 
Despite these advances, immunotherapy for HCC is 
currently only applicable to patients with advanced- stage 
disease and largely not curative in intent. Furthermore, 
the question of how to manage disease that progresses 
after ICI therapy remains unanswered. Additionally, the 
use of immunotherapy for early- stage disease remains 
largely investigational. As additional trials continue to 
report results, more options may become available for 
later lines of therapy. Future trials are needed to address 
the impact of immunotherapy in combination strate-
gies with locoregional approaches, to assist oncologists 
and their patients in balancing the potential for harm 
and benefit in early- stage cancer. In the future, the 
indications for existing therapies are likely to continue 
to expand and novel combinations may be approved. 
These guidelines will be updated as the field continues 
to develop.
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